Conference Day 2, May 23
8:30 am Check-In & Coffee
8:55 am Chair’s Opening Remarks
Evolution & Innovation: Navigating Recent Approvals, Charting Future Directions, & Brainstorming to Reduce Patient Burden
9:00 am Mapping the Past, Present, & Future of Cell Engager Therapies
Synopsis
- Revisit the recent development landscape of cell engagers within 7 recent approvals
- Understand which mechanisms, modalities, and formats are demonstrating promise towards developing the next approved cell engagers
- Reimagine future directions for cell engagers for both mono and combination therapies
9:30 am Panel Discussion: Brainstorming Combinations With CART, DDR, Cytokine-Based Therapies & Other Cell Engagers
Synopsis
- Discuss potential benefits and risks of combining cell engagers with alternate cancer therapies for personalized treatment strategies
- How can cell engager combinations be developed to reduce potential relapse while reducing the patient burden of treatment?
- Can these combinations mitigate T cell exhaustion to improve efficacy across cancer types and reduce patient burden?
10:30 am Morning Refreshments & Networking
Pursuing the Next Generation of Cell Engagers to Create Robust Immune Responses
11:00 am A First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody (PIT565) for the Treatment of B Cell Malignancies
Synopsis
- PIT565 is a first-in-class, CD19xCD3xCD2, IgG-like, trispecific antibody that targets CD19+ cells and at the same time engages CD3 and CD2 (a costimulatory receptor) on T cells, which leads to redirected T-cell cytotoxicity toward CD19-positive malignant B cell
- Preclinical data demonstrate more robust anti-tumor response and overall T cell effector functions compared with the bispecific control
- PIT565 is currently in a Phase I, open-label study to characterize the safety and tolerability of PIT565 in patients with R/R B-NHL and R/R B-ALL to determine recommended dose(s), schedule(s), and route(s) of administration for future studies, as well as to estimate the preliminary antitumor activity of PIT565
11:30 am Developing a Highly Specific ImmTAC Against PIWIL1, a Promising Novel Colorectal Cancer Target
Synopsis
Exploring a program case study accelerating towards clinic
An overview of target selection processes and engineering to ensure specific and minimize off target activity
12:00 pm Accessing Intracellular Cancer Targets via Potent & Specific TCR Mimetic (TCRm)-Based T Cell Engagers
Synopsis
- Previously unreachable target classes amenable to TCRm-based T Cell engagers
- Differences and similarities between soluble TCR and TCRm-based T cell engager approaches
- Unique challenges and opportunities in developing TCRm-based T Cell Engagers
12:30 pm Lunch & Networking
1:30 pm Empowering Antibodies to Target pHLA through NextCore TCR-Like Antibodies
Synopsis
- Combining combinatorial and bioinformatical approaches to develop unique TCR-Like antibodies
- Highly specific and potent T cell engagers guided by TCR-Like antibodies towards clinical valuable intracellular targets
2:00 pm Targeting Alternative T cell Effector Pathways to Enhance the Activity of CD3-Engaging Bispecific Antibodies
Synopsis
- Regeneron’s approach to improving cytotoxic T cell activity by adding co-stimulatory targeted biologics
- Examples from hematological and solid tumors
- Exploring what are the optimal co-stimulatory agents to activate T cells in combination with CD3 bispecifics?
2:30 pm Afternoon Break
Moving Beyond T-Cells & Unlocking More Immune Cells to Take Action & Drive Tumor Killing
2:45 pm Developing Ex Vivo Precision Gene Engineered B Cell Medicines to Create Sustainable Anti-Tumor Activity & Overcome Pharmacokinetic Shortcomings of BiTEs
Synopsis
- Exploring BiTE-expressing BECMs associated with reduced tumor burden in patientderived xenograft models
- Achieving clinically meaningful serum levels of BiTE
3:15 pm Exploiting Phagocytosis With Macrophage Engagers to Enhance Tumor Killing in Solid Tumors
Synopsis
- Advantage of inducing cancer death and clearance by implementing macrophage phagocytosis as compared to T cell engagers
- Explore the development challenges of macrophage engagers in comparison to alternate cell types
- Utilize innate immune cells for improved targeting of cancers in solid tumors